JCN Network - Home
JCN Newswire
 Search:    Companies  | Annual Reports  |  CSR  | News Alerts  |  Japanese   
Company
News Sectors
Automotive
Chemicals
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Tech
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
Trade Shows
News Alerts
News Search
Photo Gallery
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
Bookmark and Share
Kikkoman Finds Soy Sauce Bacteria Effective Against Allergies
 

Tokyo, Mar 9, 2006 (JCN) - Kikkoman Corporation has discovered that lactic acid bacteria derived from soy sauce and other fermented foods are effective against allergies.

Specifically, the company has elucidated that tetragenococcus halophilus Th221, a kind of plant-derived lactic acid bacteria found in soy sauce, can induce the generation of interleukin 12 (IL-12), a substance that helps alleviate allergic symptoms.

In recent joint research with the Tokyo University of Agriculture, Kikkoman also discovered that several other plant-derived lactic acid bacteria from fermented foods, such as Leuconostoc mesenteroides, are able to induce the generation of IL-12.

Furthermore, in experiments on mice, they confirmed that these bacteria help alleviate allergic symptoms. In particular, their administration reduces serum IgE levels, an indicator of allergy.

Details of the research will be presented at the Annual Meeting of the Japan Society for Bioscience, Biotechnology, and Agrochemistry 2006, to be held in Kyoto from March 25.

By Aki Tsukioka Contributor

Copyright © 2010 JCN. All rights reserved. A division of Japan Corporate News Network KK.



ACN Newswire

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)

 Recent  Clinical Trials News   RSS  
Astellas to Move Clinical Development Base to U.S. (Mar 4, 2008)
Daiichi Sankyo Teams with U.S. Firm on Hypertensive Drug (Aug 22, 2007)
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder (Jan 25, 2007)
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy (Jan 10, 2007)
Shionogi Reports Results of Phase III Clinical Trials of Idiopathic Pulmonary Fibrosis Treatment S-7701 (Dec 26, 2006)
 
  
CSR Report Download
Annual Reports

  More >>    
Most Popular


Copyright © 2010 JCN Newswire - Japan Corporate News Network (JCN) K.K.
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)